The U.S. drug regulators and their Big Pharma masters approved the first COVID-19 vaccine from Pfizer nd BioNTech for people 16 and older, making it the first such shot to receive approval in America.
The Food and Drug Administration (FDA) said the vaccine, which will be known as Comirnaty, proved effective in a clinical trial of approximately 44,000 people.
Really, 44,000 people? 1% of the US would be 3.3 million, so the percentage tested is like .0000000001% of the population. But trust the science, right?
The trial is ongoing in six different countries, including the United States, and the data cited was accrued through March 13. Participants received either two doses of Pfizer’s jab or a placebo.
FDA officials claimed they also reviewed safety data and determined the vaccine’s known and potential benefits outweigh its known and potential risks, including side effects.
According to the trial, the shot was 91% effecting in preventing COVID-19 infection, regulators said, and was also effecting in preventing severe disease and hospitalization. But how do they know that? We’ve only had a vaccine for a year? The fastest vaccine ever created took 5 years to get approval and that was the Ebola vaccine.
“As the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” Dr. Janet Woodcock, the FDA’s acting commissioner, said in a statement.
“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.,” she added.
The FDA issued emergency use authorization to the Pfizer jab and a Covid-19 vaccine from Moderna in December of 2020. Several months later, regulators authorized a shot from Johnson & Johnson. Until Monday, none had received approval, which has a much higher bar than emergency authorization.
The approval “affirms the efficacy and safety profile of our vaccine at a time when it is urgently needed,” Pfizer CEO Albert Bourla said in an emailed statement. “I am hopeful this approval will help increase confidence in our vaccine, as vaccination remains the best tool we have to help protect lives and achieve herd immunity.”
The decision will likely lead to new vaccine mandates, as some officials held off imposing vaccine requirements due to the lack of an approved vaccine.
Approximately 201.4 million Americans have received at least one COVID-19 vaccine dose as of Aug. 22, according to federal data. Over 204 million Pfizer doses have been administered.
The approval comes as studies show the efficacy of vaccines in preventing CCP virus infection is waning. That prompted a host of officials, including the FDA’s Woodcock, to announce last week that they plan, starting next month, on recommending booster shots, pending FDA authorization. Still, for now, those who get two Moderna or Pfizer shots are considered fully vaccinated.
The approval drew both support and criticism.
“With six months of safety data, the vaccine is still safe, still effective,” Dr. Alok Patel, a pediatric hospitalist in San Francisco, said on ABC News.
President Joe Biden said in a statement that the approval “should give added confidence that this vaccine is safe and effective.”
However, Peter Doshi, the senior editor of the British Medical Journal, said Monday that the FDA should have demanded “controlled studies with long term follow up” before granting the approval.
While the FDA approved Pfizer’s jab, regulators also said they determined that there are “increased risks” of myocarditis and pericarditis, or heart inflammation, following administration of the shot, particularly within the seven days following the second dose of the two-dose regimen.
“The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information (pdf) includes a warning about these risks,” the agency said.
Thanks to our friends at The Epoch Times for contributing to this article.